Charrier M, et al. - Researchers explored the links between systemic inflammatory or innate immune markers and prognosis in patients with lung cancer by means of a prospective and concomitant study. Participants were 148 advanced treatment-naive non–small cell lung cancer (NSCLC) patients eligible for first-line platinum-based chemotherapy. For fresh NK cell phenotyping. They analyzed data on leukocytes, neutrophils and monocyte counts and lactate dehydrogenase (LDH) levels. In univariate analysis, they observed poor overall survival (OS) in relation to monocytosis, neutrophilia, leucocytosis, high LDH and sBAG6 levels and reduced levels of NCR3 transcripts among all studied markers. They also observed the association of the levels of NCR3 transcripts with age, number of metastatic sites, monocyte counts, LDH and sBAG6 levels. Findings revealed an association between neutrophilia and high sBAG6 levels. The multivariate analysis revealed an independent association of NCR3 with both OS and progression-free survival. Overall, these biomarkers were entangled; parameters related to an inflammatory process were associated with reduced levels of NCR3 transcripts.